scholarly journals The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients

2009 ◽  
Vol 45 (17) ◽  
pp. 3064-3073 ◽  
Author(s):  
Chantal C. Orgéas ◽  
Per Hall ◽  
Sara Wedrén ◽  
Paul W. Dickman ◽  
Kamila Czene
Keyword(s):  
Endometrial Cancer ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Menopausal Hormone Therapy ◽  
Tumour Characteristics

scholarly journals Menopausal hormone therapy and mortality among endometrial cancer patients in the NIH-AARP Diet and Health Study

2015 ◽  
Vol 26 (8) ◽  
pp. 1055-1063 ◽  
Author(s):  
Ashley S. Felix ◽  
Hannah Arem ◽  
Britton Trabert ◽  
Gretchen L. Gierach ◽  
Yikyung Park ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Menopausal Hormone Therapy ◽  
Health Study

MENOPAUSAL HORMONOTHERAPY IN ONCOGYNECOLOGIC PATIENTS

2017 ◽  
Vol 63 (6) ◽  
pp. 843-854
Author(s):  
Olga Novikova ◽  
Yelena Ulrikh ◽  
V. Nosov ◽  
A. Charkhifalakyan
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Endometrial Cancer ◽  
Hormone Replacement Therapy ◽  
Hormone Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Menopausal Hormone Therapy ◽  
Oncological Safety

There is presented the review of domestic and foreign references on the conserved oncological safety of the use of menopausal hormone therapy after treatment for endometrial cancer, cervical cancer, borderline and malignant ovarian tumors, various variants of sarcomas of the uterus, vulva and vaginal cancer. To the opinion of the authors the refusal to prescribe menopausal hormone therapy to patients with oncogynecologic diseases in the anamnesis is usually not justified, the category of patients, to whom hormone replacement therapy is contraindicated, is well described and mentioned in the text. In other cases sex hormones can be used to treat menopausal symptoms and improve the quality of life of patients.

scholarly journals Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?

2012 ◽  
Vol 132 (2) ◽  
pp. 417-426 ◽  
Author(s):  
Britton Trabert ◽  
Nicolas Wentzensen ◽  
Hannah P. Yang ◽  
Mark E. Sherman ◽  
Albert R. Hollenbeck ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Endometrial Cancer Risk ◽  
Estrogen Plus Progestin

Vaginal bleeding during menopause hormone therapy. Is it always endometrial cancer? How to choose the appropriate tactics for examination and management of patients?

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (5) ◽  
pp. 37-43
Author(s):  
Anna E. Protasova ◽  
Irina A. Solntseva ◽  
Ekaterina N. Vandeeva
Keyword(s):  
Endometrial Cancer ◽  
Hormone Therapy ◽  
Genital Tract ◽  
Vaginal Bleeding ◽  
Abnormal Uterine Bleeding ◽  
Uterine Bleeding ◽  
Menopausal Hormone Therapy ◽  
Modern Analysis ◽  
Menopause Hormone Therapy ◽  
Postmenopausal Vaginal Bleeding

The article provides an overview of the possible causes of bleeding from the genital tract in peri- and postmenopausal women. The correct approach to patients with abnormal uterine bleeding during menopausal hormone therapy is described. A modern analysis of data on the diagnosis and treatment of postmenopausal vaginal bleeding against the background of menopausal hormone therapy was carried out. The modern possibilities of endometrial diagnostics and treatment are shown.

Endometrial hyperplasia: without atypia and with atypia

GYNECOLOGY ◽  
2021 ◽  
Vol 23 (1) ◽  
pp. 18-24
Author(s):  
Maksim A. Sabantsev ◽  
Svetlana V. Shramko ◽  
Vladimir G. Levchenko ◽  
Oleg A. Volkov ◽  
Tatyana V. Tretyakova
Keyword(s):  
Risk Factors ◽  
Endometrial Cancer ◽  
Hormone Therapy ◽  
Research Methods ◽  
Endometrial Hyperplasia ◽  
Menopausal Hormone Therapy ◽  
Pubmed Database ◽  
Gynecological Diseases ◽  
Current Classification

The article analyzes and presents data for the last 70 years from the PubMed database on endometrial hyperplasia (EH), which is one of the leaders in the structure of gynecological diseases and the main predictor of endometrial cancer (EC). The chronicle of the EH classification is highlighted with a focus on changing the designation and relevance of adenomatous EH. It is shown how the current classification of EH, due to the fact that a large number of synonyms is limited by two options, allows to maximize the reproducibility of the diagnosis, improve the interaction of the obstetrician-gynecologist with the pathologist and reduce the treatment inefficiency. The results of modern studies on the prevalence and risk factors of EH and EC differ from previously accepted ones and destroy the Bohman triad. The risks of EH development with tamoxifen and menopausal hormone therapy are determined. The data of current research methods aimed at the diagnosis of EH and EC are indicated. The differences in etiopathogenesis, prevalence, diagnosis, risk factors for development and progression to the malignant process presented in the review represent two types of EH (without atypia and with atypia) as completely different endometrial diseases included in the same classification.

scholarly journals Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2195
Author(s):  
Clemens B. Tempfer ◽  
Ziad Hilal ◽  
Peter Kern ◽  
Ingolf Juhasz-Boess ◽  
Günther A. Rezniczek
Keyword(s):  
Endometrial Cancer ◽  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Cochrane Central Register ◽  
Obese Women ◽  
Hazard Ratios ◽  
Appropriate Treatment ◽  
Central Register ◽  
Increased Risk ◽  
Micronized Progesterone

Background: Menopausal hormone therapy (MHT) is an appropriate treatment for women with the climacteric syndrome. The estrogen component of MHT effectively alleviates climacteric symptoms but also stimulates the endometrium and thus may increase the risk of endometrial cancer (EC). Materials and Methods: We performed a systematic literature search of the databases PubMed and Cochrane Central Register of Controlled Trials to identify controlled and uncontrolled clinical trials reporting on the prevalence and/or incidence of EC among women using MHT. Results: 31 publications reporting on 21,306 women with EC diagnosed during or after MHT were identified. A significantly reduced risk of EC among continuous-combined (cc)MHT users with synthetic progestins (SPs) was demonstrated in 10/19 studies with odds ratios (ORs)/hazard ratios (HRs) between 0.24 and 0.71. Only one study documented an increased risk of EC among long-term users (≥10 years), not confirmed in three other sub-group analyses of women with ≥6, ≥5, and >10 years of ccMHT use. A significantly increased risk of EC among users of sequential-combined (sc)MHT with SPs was demonstrated in 6/12 studies with ORs/HRs between 1.38 and 4.35. Number of days of progestin per month was a significant modulator of EC risk. A decreased risk of EC was seen in obese women. Two studies documented an increased risk of EC among users of cc/scMHT with micronized progesterone. A significantly increased risk of EC among estrogen-only MHT users was demonstrated in 9/12 studies with ORs/HRs between 1.45 and 4.46. The adverse effect of estrogen-only MHT was greatest among obese women. Conclusion: ccMHT with SPs reduces the risk of EC, whereas estrogen-only MHT increases the risk. scMHT with SPs and cc/scMHT with micronized progesterone increase the risk of EC depending on type of progestin, progestin dosage, and duration of MHT use.

scholarly journals Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort

Cancer ◽  
2007 ◽  
Vol 109 (7) ◽  
pp. 1303-1311 ◽  
Author(s):  
James V. Lacey ◽  
Michael F. Leitzmann ◽  
Shih-Chen Chang ◽  
Traci Mouw ◽  
Albert R. Hollenbeck ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
National Institutes Of Health ◽  
Health Study ◽  
Study Cohort
Sign in / Sign up

Export Citation Format

Share Document